In order to further understand the molecular mechanism of Nrf2 on the tumor mutation burden rate in AML, we examined transcriptome sequencing (RNAseq) in the above patients, removed the unqualified samples, and analyzed the difference of gene expression (GEO accession: GSE160499). The gene discussed is NFE2L2; the disease is acute myeloid leukemia.